Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Zaleplon and triazolam in humans: acute behavioral effects and abuse potential
Autore:
Rush, CR; Frey, JM; Griffiths, RR;
Indirizzi:
Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21224 USA Johns Hopkins Univ Baltimore MD USA 21224 av Sci, Baltimore, MD 21224 USA Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21224 USA Johns Hopkins Univ Baltimore MD USA 21224 urosci, Baltimore, MD 21224 USA
Titolo Testata:
PSYCHOPHARMACOLOGY
fascicolo: 1, volume: 145, anno: 1999,
pagine: 39 - 51
Fonte:
ISI
Lingua:
ENG
Soggetto:
INVESTIGATING DRUG REINFORCEMENT; MULTIPLE-CHOICE PROCEDURE; BENZODIAZEPINE RECEPTOR; PHARMACOLOGICAL TREATMENT; NORMAL VOLUNTEERS; SEDATIVE ABUSERS; SLEEP DISORDERS; SUBJECT RATINGS; HYPNOTIC DRUGS; SELF-INJECTION;
Keywords:
zaleplon; triazolam; benzodiazepine; hypnotics; learning; memory; abuse potential; human;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Griffiths, RR Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21224 USA Johns Hopkins Univ Baltimore MD USA 21224 ore, MD 21224 USA
Citazione:
C.R. Rush et al., "Zaleplon and triazolam in humans: acute behavioral effects and abuse potential", PSYCHOPHAR, 145(1), 1999, pp. 39-51

Abstract

Zaleplon, a pyrazolopyrimidine that is under development as a hypnotic, produces its pharmacological effects at the benzodiazepine-recognition site on the GABAA benzodiazepine-receptor complex. Unlike most benzodiazepines, zaleplon binds selectively to the BZ(1) (omega(1)) subtype of the benzodiazepine receptor. The present study compared the acute subject-rated effects, performance-impairing effects, and abuse potential of zaleplon and triazolam, a triazolobenzodiazepine hypnotic, in 14 healthy volunteers with histories of drug abuse. Zaleplon (25, 50, and 75 mg), triazolam (0.25, 0.5, and 0.75 mg) and placebo were administered orally in this double-blind, crossover study. Zaleplon and triazolam produced comparable dose-related effects onseveral subject-rated drug-effect questionnaires. Zaleplon and triazolam also produced comparable dose-dependent decrements on several performance tasks including balance, circular lights, digit-enter and recall, DSST, picture recall/recognition and repeated acquisition. Same-day and next-day subject-rated measures reflecting abuse potential (e.g., drug liking, good effects, and monetary street value) also suggest that zaleplon and triazolam were comparable. The only notable between-drug difference observed in the present study was that the time-action function of zaleplon differed from that of triazolam. The onset time, time to maximum drug effect, and duration of action were shorter with zaleplon than triazolam. Thus, despite its non-benzodiazepine structure and unique benzodiazepine-receptor binding profile, the behavioral pharmacological profile of zaleplon is similar to that of triazolam.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 13:30:04